Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05731128
- Locations
- 🇺🇸
Om Research- Site Number : 8400029, Apple Valley, California, United States
🇺🇸Advanced Research Institute - New Port Richey- Site Number : 8400026, New Port Richey, Florida, United States
🇺🇸TLC Clinical Research- Site Number : 8400020, Beverly Hills, California, United States
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Registration Number
- NCT05726682
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 203
- Registration Number
- NCT05720455
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT05718258
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400002, Miami, Florida, United States
🇺🇸Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
🇩🇪Investigational Site Number : 2760001, Kiel, Germany
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05712278
- Locations
- 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia
A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT05684341
- Locations
- 🇨🇳
Tri-Service General Hospital - Investigational Site Number: 1580014, Taipei city, Taiwan
🇨🇳Kaohsiung Veterans General Hospital - Investigational site number 1580010, Kaohsiung, Taiwan
🇨🇳Far-Eastern Memorial Hospital - Investigational Site Number: 1580004, New Taipei city, Taiwan
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT05680298
- Locations
- 🇨🇳
Beijing Children's hospital, Beijing, China
Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)
- Conditions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT05671770
- Locations
- 🇦🇪
Cleveland Clinic AbuDhabi, Abu Dhabi, United Arab Emirates
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia